|
|
Zhang, Z. and B. Zehnder, et al. (2016). "Visualization of Hepatitis B Virus Entry: Novel Tools and Approaches to Directly Follow Virus Entry into Hepatocytes." FEBS Lett.
Blank, A. and C. Markert, et al. (2016). "First-in-human application of the first-in-class hepatitis B and hepatitis D virus entry inhibitor myrcludex B." J Hepatol.
Bogomolov, P. and A. Alexandrov, et al. (2016). "Treatment of chronic hepatitis D with the entry inhibitor myrcludex B - first results of a Phase Ib/IIa study." J Hepatol.
Li, W. and S. Urban (2016). "Entry of hepatitis B and hepatitis D virus into hepatocytes: Basic insights and clinical implications." J Hepatol 64(1 Suppl): S32-40.
Uhl, P. and F. Helm, et al. (2016). "A liposomal formulation for the oral application of the investigational hepatitis B drug Myrcludex B." Eur J Pharm Biopharm 103: 159-66.
Lempp, F. A. and B. Qu, et al. (2016). "Hepatitis B Virus Infection of a Mouse Hepatic Cell Line Reconstituted with Human Sodium Taurocholate Cotransporting Polypeptide." J Virol 90(9): 4827-31.
Lempp, F. A. and P. Mutz, et al. (2016). "Evidence that hepatitis B virus replication in mouse cells is limited by the lack of a host cell dependency factor." J Hepatol 64(3): 556-64.
Urban, S. (2016). "Liver capsule: Entry and entry inhibition of hepatitis B virus and hepatitis delta virus into hepatocytes." Hepatology 63(2): 633.
Liang, T. J. and T. M. Block, et al. (2015). "Present and future therapies of hepatitis B: From discovery to cure." Hepatology 62(6): 1893-908.
Hoh, A. and M. Heeg, et al. (2015). "Hepatitis B Virus-Infected HepG2hNTCP Cells Serve as a Novel Immunological Tool To Analyze the Antiviral Efficacy of CD8+ T Cells In Vitro." J Virol 89(14): 7433-8.
Haag, M. and U. Hofmann, et al. (2015). "Quantitative bile acid profiling by liquid chromatography quadrupole time-of-flight mass spectrometry: monitoring hepatitis B therapy by a novel Na(+)-taurocholate cotransporting polypeptide inhibitor." Anal Bioanal Chem 407(22): 6815-25.
Slijepcevic, D. and C. Kaufman, et al. (2015). "Impaired uptake of conjugated bile acids and hepatitis b virus pres1-binding in na(+) -taurocholate cotransporting polypeptide knockout mice." Hepatology 62(1): 207-19.
Lempp, F. A. and S. Urban (2014). "Inhibitors of hepatitis B virus attachment and entry." Intervirology 57(3-4): 151-7.
Oehler, N. and T. Volz, et al. (2014). "Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism." Hepatology 60(5): 1483-93.
Watashi, K. and S. Urban, et al. (2014). "NTCP and beyond: opening the door to unveil hepatitis B virus entry." Int J Mol Sci 15(2): 2892-905.
Ni, Y. and F. A. Lempp, et al. (2014). "Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes." Gastroenterology 146(4): 1070-83.
Baumert, T. F. and L. Meredith, et al. (2014). "Entry of hepatitis B and C viruses - recent progress and future impact." Curr Opin Virol 4: 58-65.
Nkongolo, S. and Y. Ni, et al. (2014). "Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor." J Hepatol 60(4): 723-31.
Gubeli, R. J. and K. Schoneweis, et al. (2013). "Pharmacologically triggered hydrogel for scheduling hepatitis B vaccine administration." Sci Rep 3: 2610.
Muller, T. and S. Mehrle, et al. (2013). "Liver imaging with a novel hepatitis B surface protein derived SPECT-tracer." Mol Pharm 10(6): 2230-6.
Lamas, L. O. and T. T. Schmidt, et al. (2013). "Proteoglycans act as cellular hepatitis delta virus attachment receptors." PLoS One 8(3): e58340.
Schieck, A. and A. Schulze, et al. (2013). "Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts." Hepatology 58(1): 43-53.
Volz, T. and L. Allweiss, et al. (2013). "The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus." J Hepatol 58(5): 861-7.
Meier, A. and S. Mehrle, et al. (2013). "Myristoylated PreS1-domain of the hepatitis B virus L-protein mediates specific binding to differentiated hepatocytes." Hepatology 58(1): 31-42.
Schulze, A. and K. Mills, et al. (2012). "Hepatocyte polarization is essential for the productive entry of the hepatitis B virus." Hepatology 55(2): 373-83.
Lutgehetmann, M. and L. V. Mancke, et al. (2012). "Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation." Hepatology 55(3): 685-94.
von Hahn, T. and A. Schulze, et al. (2011). "The novel immunosuppressive protein kinase C inhibitor sotrastaurin has no pro-viral effects on the replication cycle of hepatitis B or C virus." PLoS One 6(9): e24142.
Schieck, A. and T. Muller, et al. (2010). "Solid-phase synthesis of the lipopeptide Myr-HBVpreS/2-78, a hepatitis B virus entry inhibitor." Molecules 15(7): 4773-83.
Ni, Y. and J. Sonnabend, et al. (2010). "The pre-s2 domain of the hepatitis B virus is dispensable for infectivity but serves a spacer function for L-protein-connected virus assembly." J Virol 84(8): 3879-88.
Urban, S. and A. Schulze, et al. (2010). "The replication cycle of hepatitis B virus." J Hepatol 52(2): 282-4.
Schulze, A. and A. Schieck, et al. (2010). "Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction." J Virol 84(4): 1989-2000.
Kim, D. H. and Y. Ni, et al. (2008). "An anti-viral peptide derived from the preS1 surface protein of hepatitis B virus." BMB Rep 41(9): 640-4.
Gudima, S. and Y. He, et al. (2008). "Primary human hepatocytes are susceptible to infection by hepatitis delta virus assembled with envelope proteins of woodchuck hepatitis virus." J Virol 82(15): 7276-83.
Petersen, J. and M. Dandri, et al. (2008). "Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein." Nat Biotechnol 26(3): 335-41.
Bohne, F. and M. Chmielewski, et al. (2008). "T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes." Gastroenterology 134(1): 239-47.
Tavakoli, S. and I. Mederacke, et al. (2008). "Peripheral blood dendritic cells are phenotypically and functionally intact in chronic hepatitis B virus (HBV) infection." Clin Exp Immunol 151(1): 61-70.
Shin, E. C. and U. Seifert, et al. (2007). "Proteasome activator and antigen-processing aminopeptidases are regulated by virus-induced type I interferon in the hepatitis C virus-infected liver." J Interferon Cytokine Res 27(12): 985-90.
Schulze, A. and P. Gripon, et al. (2007). "Hepatitis B virus infection initiates with a large surface protein-dependent binding to heparan sulfate proteoglycans." Hepatology 46(6): 1759-68.
Seitz, S. and S. Urban, et al. (2007). "Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions." EMBO J 26(18): 4160-7.
Engelke, M. and K. Mills, et al. (2006). "Characterization of a hepatitis B and hepatitis delta virus receptor binding site." Hepatology 43(4): 750-60.
Glebe, D. and S. Urban, et al. (2005). "Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes." Gastroenterology 129(1): 234-45.
Gripon, P. and I. Cannie, et al. (2005). "Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein." J Virol 79(3): 1613-22.
Urban, S. (2004). "Binding of duck carboxypeptidase D to duck hepatitis B virus." Methods Mol Med 95: 199-212.
Gripon, P. and S. Rumin, et al. (2002). "Infection of a human hepatoma cell line by hepatitis B virus." Proc Natl Acad Sci U S A 99(24): 15655-60.
Urban, S. and P. Gripon (2002). "Inhibition of duck hepatitis B virus infection by a myristoylated pre-S peptide of the large viral surface protein." J Virol 76(4): 1986-90.
Urban, S. and S. Urban, et al. (2001). "Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism." Proc Natl Acad Sci U S A 98(9): 4984-9.
Breiner, K. M. and S. Urban, et al. (2001). "Envelope protein-mediated down-regulation of hepatitis B virus receptor in infected hepatocytes." J Virol 75(1): 143-50.
Urban, S. and D. L. Tyrrell (2000). "An in vitro system for the enzymological analysis of avian hepatitis B virus replication and inhibition in core particles." Antiviral Res 45(3): 185-97.
Urban, S. and C. Schwarz, et al. (2000). "Receptor recognition by a hepatitis B virus reveals a novel mode of high affinity virus-receptor interaction." EMBO J 19(6): 1217-27.
Urban, S. and C. Kruse, et al. (1999). "A soluble form of the avian hepatitis B virus receptor. Biochemical characterization and functional analysis of the receptor ligand complex." J Biol Chem 274(9): 5707-15.
Poussin, K. and H. Dienes, et al. (1999). "Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas." Int J Cancer 80(4): 497-505.
Sirma, H. and R. Weil, et al. (1998). "Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome." Oncogene 16(16): 2051-63.
Breiner, K. M. and S. Urban, et al. (1998). "Carboxypeptidase D (gp180), a Golgi-resident protein, functions in the attachment and entry of avian hepatitis B viruses." J Virol 72(10): 8098-104.
Urban, S. and K. M. Breiner, et al. (1998). "Avian hepatitis B virus infection is initiated by the interaction of a distinct pre-S subdomain with the cellular receptor gp180." J Virol 72(10): 8089-97.
Urban, S. and E. Hildt, et al. (1997). "Isolation and molecular characterization of hepatitis B virus X-protein from a baculovirus expression system." Hepatology 26(4): 1045-53.
Hildt, E. and S. Urban, et al. (1996). "Isolation of highly purified, functional carboxy-terminally truncated hepatitis B virus middle surface protein activators from eucaryotic expression systems." Hepatology 24(3): 502-7. |
|
发表于 2016-5-10 00:42:02
